Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 8/20 | 0.41 |
| ▸ | FAAH | O00519 | 5/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.30 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1982533 | 0.89 | FAAH (0.39) | MGLLFAAHSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL43497 | 0.89 | MGLL (0.48) | MGLLFAAHPTGS1PTGS2LMNA | |
| SCHEMBL8626067 | 0.88 | MGLL (0.41) | MGLLFAAHPTGS1PTGS2LMNA | |
| SCHEMBL8632296 | 0.88 | MGLL (0.41) | MGLLFAAHPTGS1PTGS2LMNA | |
| SCHEMBL8629338 | 0.88 | MGLL (0.41) | MGLLFAAHPTGS1PTGS2LMNA | |
| SCHEMBL8829436 | 0.88 | MGLL (0.41) | MGLLFAAHPTGS1PTGS2LMNA | |
| SCHEMBL7044109 | 0.88 | MGLL (0.52) | MGLLFAAHPTGS1PTGS2LMNA | |
| SCHEMBL4304987 | 0.88 | MGLL (0.52) | MGLLFAAHPTGS1PTGS2LMNA | |
| SCHEMBL4309970 | 0.88 | MGLL (0.52) | MGLLFAAHPTGS1PTGS2LMNA | |
| SCHEMBL4306818 | 0.88 | MGLL (0.52) | MGLLFAAHPTGS1PTGS2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522916-B2 | A1 adenosine receptor antagonists | WILSON CONSTANCE NEELY (US) | 2016-12-20 | — | — | US | disclosed |
| US-20140031375-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | WILSON CONSTANCE NEELY (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2222676-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | Endacea, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009086077-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ENDACEA, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090068101-A9 | A1 Adenosine Receptor Antagonists | ENDACEA, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| EP-1636229-A4 | A1 ADENOSINE RECEPTOR ANTOGONISTS | ENDACEA INC (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20070282105-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ENDACEA, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070274910-A1 | e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility | ENDACEA, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-7247639-B2 | A1 adenosine receptor antagonists | ENDACEA, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1636230-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | Endacea, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1636229-A2 | A1 ADENOSINE RECEPTOR ANTOGONISTS | Endacea, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20050187226-A1 | A1 adenosine receptor antagonists | ENDACEA, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2005009343-A2 | A1 ADENOSINE RECEPTOR ANTOGONISTS | ENDACEA, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2004110379-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ENDACEA, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282105-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA3, ADORA2A | MGLL 3223/4885FAAH 786/4885PTGS1 2818/4885 |
| US-20070274910-A1 | e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility | HRH3, HRH1, HRH2 | MGLL 4141/4885FAAH 42/4885PTGS1 276/4885 |
| US-20140031375-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | MGLL 3474/4885FAAH 940/4885PTGS1 505/4885 |
| US-20050187226-A1 | A1 adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | MGLL 3473/4885FAAH 664/4885PTGS1 930/4885 |
| US-20090068101-A9 | A1 Adenosine Receptor Antagonists | ADORA1, ADORA3, ADORA2A | MGLL 4276/4885FAAH 51/4885PTGS1 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.